Stockysis — AI-Powered Stock News & Sentiment Analysis

HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.7%

Neg 0% Neu 88.7% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.

Comments

No comments yet. Be the first!